materialise

innovators you can count on

Q2 & H1 2026 Financial Results

Conference call | August 27, 2026

www.materialise.com | NASDAQ & EURONEXT: MTLS

Safe Harbor Summary

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, our estimates for revenue, Adjusted EBITDA, Adjusted EBIT, our results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies (including how our business, results of operations and financial condition could be impacted by the current armed geopolitical conflicts around the world and governmental responses thereto, inflation, increased labor, energy and materials costs), policy changes resulting from the U.S. presidential administration, changes in tariffs and trade restrictions, and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this presentation, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this presentation. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company's actual results to differ materially from our expectations, including risk factors described in the company's annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. There are a number of risks and uncertainties that could cause the company's actual results to differ materially from the forward-looking statements contained in this presentation.

This presentation includes non-IFRS financial measures, including EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA. These measures are supplemental measures of financial performance that are not required by, or presented in accordance with, international financial reporting standards (“IFRS”). Please refer to the Appendix of this presentation for a reconciliation of such non-IFRS financial measures to the most directly comparable financial measures prepared in accordance with IFRS.

Agenda

- Q2 2026 Business Highlights
- Q2 2026 Financial Highlights
- Q2 & H1 2026 Financial Results
- 2026 Financial Guidance
- Q&A

Brigitte de Vet-Veithen
CEO

Koen Berges
CFO

Q2 2026 Business Update

H1 report published

- To be consulted on our Investor Relations website
- In compliance with Euronext requirements

Strengthening Executive Committee

- CHRO: Annelies Missotten
- CDIO: Philippe Verlinde
- EVP Medical Koen Peters leaving the company

30 year anniversary of Materialise in the U.S.

- Instrumental in global success
- Driver of various strategic acquisitions

Q2 2026 Business Update

Medical – ***Making the Exceptional Accessible***

- Hospital Forum reflects continued maturation of the personalized care market
- Investment in Replasia expands Materialise's personalized hip care portfolio
- Materialise offers complete minimally invasive MIOS workflow



Software – ***Growing Our Software Ecosystem***

- Continued rollout of CO-AM with release of CO-AM Pro
- Early adopter programs for NPI and Enterprise versions of CO-AM

Manufacturing – ***Delivering Certified Additive Manufacturing Solutions***

- Portfolio choices: Completed the divestiture of RapidFit and Eyewear business
- Aerospace:
  - +40% YoY revenue growth
  - Materialise named official Workbench for Lufthansa Technik metal parts
- Defense: Materialise leads consortium to strengthen trusted access to spare parts for Belgian defense

materialise
innovators you can count on

Q2 2026 – Financial Highlights

- **Revenue** of 70.1 mEUR, representing an increase of 8.1% from Q2 2025
- **Gross Profit** of 39.8 mEUR, representing 56.8% of revenue
- **Adjusted EBIT** of 3.9 mEUR, representing 5.5% of revenue
- **Net profit** of 3.3 mEUR, representing 6 EUR-ct. per share
- **Net Cash** position of 74.2 mEUR, representing an increase of 3.4 mEUR from year-end 2025, while YTD 5.2 mEUR was invested in share buybacks

Q2 & Half-Year 2026
Consolidated Revenue



Q2 2026 Revenue by Segment



[Data in kEUR unless notes otherwise. All numbers and percentages rounded]

- Quarterly revenue of 70.1 mEUR, representing an increase of 8.1% compared to Q2 2025
- Q2 revenue growth of 12% in our Medical segment. Manufacturing segment shows 7% Q2 growth driven by strong performance of our series manufacturing focus segments
- 46.5 mEUR of deferred revenue from software licenses and maintenance carried on our balance sheet at the end of Q2 2026

Q2 & Half-Year 2026

Consolidated Adjusted EBITDA & EBIT





[Data in kEUR unless noted otherwise. All numbers and percentages rounded]

- Significant growth in Adjusted EBIT and Adjusted EBITDA compared to PY both in Q2 as well as throughout H1 2026
- Increased revenue combined with continued cost control drive higher operational profitability

Q2 & Half-Year 2026

Medical Segment





[Data in kEUR unless noted otherwise. All numbers and percentages rounded]

- Q2 2026 revenue increased 12% to 36.9 mEUR
  - Revenue from medical devices & services increased 19%, driven by growth in both partner and direct sales
  - Revenue from medical software decreased by -4%
- Q2 2026 Adjusted EBITDA grew to 11.6 mEUR, representing an Adjusted EBITDA margin of 31%

Q2 & Half-Year 2026

Software Segment



[Data in kEUR unless noted otherwise. All numbers and percentages rounded]



- Q2 2026 revenue decreased by 2.7% to 9.6 mEUR compared to Q2 2026
- Recurring revenue representing 86% of total revenue in Q2 2026
- Q2 2026 Adjusted EBITDA decreased to 1.0 mEUR, representing an Adjusted EBITDA margin of 10%. Over H1 2026 Adj. EBITDA increased by 7% to 2.1 mEUR

Q2 & Half-Year 2026

Manufacturing Segment



Revenue



Adj. EBITDA

[Data in kEUR unless noted otherwise. All numbers and percentages rounded]

- Q2 2026 revenue increased by 6.7% to 23.6 mEUR compared to Q2 2025
- Revenue growth is driven by strategic segments in series manufacturing partly offset by continued soft prototyping demand
- Q2 2026 Adjusted EBITDA improved to (0.3) mEUR. Over H1 2026 Adj EBITDA improved to breakeven level

Income Statement Highlights

materialise
innovators you can count on

	Q2		Half-Year	
(in thousands of euros, except where indicated)	2026	2025	2026	2025
Revenue	70,073	64,831	136,349	131,210
Cost of sales	(30,297)	(27,053)	(58,679)	(56,708)
Gross profit	**39,776**	**37,778**	**77,670**	**74,502**
Research & development expenses	(12,312)	(11,120)	(24,203)	(22,534)
Sales & marketing expenses	(15,209)	(15,471)	(30,644)	(30,542)
General & administrative expenses	(10,236)	(9,744)	(19,623)	(19,769)
Other income/(expenses), net	766	1,286	1,676	1,646
Operating profit/(loss)	**2,785**	**2,730**	**4,875**	**3,303**
Financial income/(expenses), net	242	(3,052)	634	(3,927)
Taxes	304	521	(358)	287
Net profit/(loss)	**3,331**	**199**	**5,152**	**(337)**
Diluted EPS (in EUR)	0.06	0.00	0.09	(0.01)
(Diluted) weighted average shares (thousands)	58,329	59,067	58,592	59,067

Gross profit margin (in %)



Diluted EPS (in EUR)



[Data in kEUR unless noted otherwise. All numbers and percentages rounded]

Other Financial Highlights

Balance Sheet items (in thousands of euros, except where indicated)	30/06/26	12/31/25
Cash and equivalents	133,735	133,918
Borrowings	59,521	63,113
Net Cash	**74,214**	**70,805**
Trade receivables	56,173	54,938
Inventories	16,846	14,904
Trade payables	19,382	20,125
Deferred income	62,553	60,867
Equity	256,268	255,482
Total balance sheet	**417,665**	**420,646**

Cash flow from operations



Capital expenditures (cash impact)



[Data in kEUR unless noted otherwise. All numbers and percentages rounded]

2026 Financial Guidance

We **maintain** our previous **revenue guidance** but **increase our Adjusted EBIT guidance** based on solid H1 results

- Expect 2026 **consolidated revenue** within 273 - 283 mEUR range

- Expect 2026 **consolidated Adjusted EBIT** within 12 - 14 mEUR range, revised upwards from our previous range of 10 – 12 mEUR

Appendix

Adjusted EBIT/EBITDA Reconciliation

	Q2		Half-Year	
[Data in kEUR unless noted otherwise. All numbers and percentages rounded]	2026	2025	2026	2025
Net profit/(loss)	**3,331**	**199**	**5,152**	**(337)**
Income taxes	(304)	(521)	358	(287)
Financial expenses	871	4,039	1,571	6,811
Financial income	(1,113)	(987)	(2,205)	(2,884)
EBIT	**2,785**	**2,730**	**4,876**	**3,303**
Depreciation & amortization	5,712	5,230	11,291	10,731
EBITDA	**8,497**	**7,960**	**16,167**	**14,034**
Share-based compensation expense	59	45	115	117
Restructuring and corporate initiatives	178	283	435	283
Impairments	689	-	756	-
Divestitures-related expenses	169	-	169	-
Adjusted EBITDA	**9,593**	**8,288**	**17,642**	**14,434**
Depreciation & amortization	(5,712)	(5,230)	(11,291)	(10,731)
Adjusted EBIT	**3,880**	**3,058**	**6,351**	**3,703**

Thank You

Contact:
Investor Relations Materialise
investors@materialise.com